vs
Tarsus Pharmaceuticals, Inc.（TARS）与Tecnoglass Inc.（TGLS）财务数据对比。点击上方公司名可切换其他公司
Tecnoglass Inc.的季度营收约是Tarsus Pharmaceuticals, Inc.的1.6倍（$245.3M vs $151.7M），Tecnoglass Inc.净利率更高（10.6% vs -5.5%，领先16.2%），Tarsus Pharmaceuticals, Inc.同比增速更快（128.4% vs 2.4%），Tarsus Pharmaceuticals, Inc.自由现金流更多（$13.0M vs $11.4M），过去两年Tarsus Pharmaceuticals, Inc.的营收复合增速更高（134.4% vs 12.8%）
Tarsus Pharmaceuticals是一家处于后期临床阶段的生物制药公司，专注于眼科、皮肤科等专科领域创新疗法的研发和商业化，主打产品针对蠕形螨睑缘炎、玫瑰痤疮等未被充分诊断的常见病症，核心市场为美国。
Tecnoglass Inc.是一家领先的建筑玻璃、铝制门窗及相关建材生产商，主要服务北美及拉美地区的住宅和商业建筑领域，为新建及翻新项目提供定制化、高能效的建筑解决方案。
TARS vs TGLS — 直观对比
营收规模更大
TGLS
是对方的1.6倍
$151.7M
营收增速更快
TARS
高出126.0%
2.4%
净利率更高
TGLS
高出16.2%
-5.5%
自由现金流更多
TARS
多$1.5M
$11.4M
两年增速更快
TARS
近两年复合增速
12.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $151.7M | $245.3M |
| 净利润 | $-8.4M | $26.1M |
| 毛利率 | — | 40.0% |
| 营业利润率 | -5.3% | 18.3% |
| 净利率 | -5.5% | 10.6% |
| 营收同比 | 128.4% | 2.4% |
| 净利润同比 | 63.8% | -44.5% |
| 每股收益（稀释后） | $-0.17 | $0.57 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收TARSTGLS
| Q4 25 | $151.7M | $245.3M | ||
| Q3 25 | $118.7M | $260.5M | ||
| Q2 25 | $102.7M | $255.5M | ||
| Q1 25 | $78.3M | $222.3M | ||
| Q4 24 | $66.4M | $239.6M | ||
| Q3 24 | $48.1M | $238.3M | ||
| Q2 24 | $40.8M | $219.7M | ||
| Q1 24 | $27.6M | $192.6M |
净利润TARSTGLS
| Q4 25 | $-8.4M | $26.1M | ||
| Q3 25 | $-12.6M | $47.2M | ||
| Q2 25 | $-20.3M | $44.1M | ||
| Q1 25 | $-25.1M | $42.2M | ||
| Q4 24 | $-23.1M | $47.0M | ||
| Q3 24 | $-23.4M | $49.5M | ||
| Q2 24 | $-33.3M | $35.0M | ||
| Q1 24 | $-35.7M | $29.7M |
毛利率TARSTGLS
| Q4 25 | — | 40.0% | ||
| Q3 25 | — | 42.7% | ||
| Q2 25 | — | 44.7% | ||
| Q1 25 | — | 43.9% | ||
| Q4 24 | — | 44.5% | ||
| Q3 24 | — | 45.8% | ||
| Q2 24 | — | 40.8% | ||
| Q1 24 | — | 38.8% |
营业利润率TARSTGLS
| Q4 25 | -5.3% | 18.3% | ||
| Q3 25 | -12.2% | 25.1% | ||
| Q2 25 | -21.6% | 24.0% | ||
| Q1 25 | -33.5% | 26.7% | ||
| Q4 24 | -36.8% | 28.0% | ||
| Q3 24 | -52.3% | 28.4% | ||
| Q2 24 | -81.6% | 23.3% | ||
| Q1 24 | -136.5% | 21.3% |
净利率TARSTGLS
| Q4 25 | -5.5% | 10.6% | ||
| Q3 25 | -10.6% | 18.1% | ||
| Q2 25 | -19.8% | 17.3% | ||
| Q1 25 | -32.1% | 19.0% | ||
| Q4 24 | -34.8% | 19.6% | ||
| Q3 24 | -48.7% | 20.8% | ||
| Q2 24 | -81.6% | 15.9% | ||
| Q1 24 | -129.4% | 15.4% |
每股收益（稀释后）TARSTGLS
| Q4 25 | $-0.17 | $0.57 | ||
| Q3 25 | $-0.30 | $1.01 | ||
| Q2 25 | $-0.48 | $0.94 | ||
| Q1 25 | $-0.64 | $0.90 | ||
| Q4 24 | $-0.57 | $1.00 | ||
| Q3 24 | $-0.61 | $1.05 | ||
| Q2 24 | $-0.88 | $0.75 | ||
| Q1 24 | $-1.01 | $0.63 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $417.3M | $104.1M |
| 总债务越低越好 | $72.4M | $174.4M |
| 股东权益账面价值 | $343.4M | $713.1M |
| 总资产 | $562.2M | $1.3B |
| 负债/权益比越低杠杆越低 | 0.21× | 0.24× |
8季度趋势，按日历期对齐
现金及短期投资TARSTGLS
| Q4 25 | $417.3M | $104.1M | ||
| Q3 25 | $401.8M | $127.1M | ||
| Q2 25 | $381.1M | $140.9M | ||
| Q1 25 | $407.9M | $160.2M | ||
| Q4 24 | $291.4M | $137.5M | ||
| Q3 24 | $317.0M | $124.8M | ||
| Q2 24 | $323.6M | $129.5M | ||
| Q1 24 | $298.5M | $138.8M |
总债务TARSTGLS
| Q4 25 | $72.4M | $174.4M | ||
| Q3 25 | $72.3M | $114.7M | ||
| Q2 25 | $72.1M | $110.6M | ||
| Q1 25 | $72.0M | $110.6M | ||
| Q4 24 | $71.8M | $111.1M | ||
| Q3 24 | $71.7M | $126.8M | ||
| Q2 24 | $71.6M | $144.7M | ||
| Q1 24 | $29.9M | $160.9M |
股东权益TARSTGLS
| Q4 25 | $343.4M | $713.1M | ||
| Q3 25 | $335.1M | $764.0M | ||
| Q2 25 | $332.6M | $736.0M | ||
| Q1 25 | $342.5M | $685.1M | ||
| Q4 24 | $224.5M | $631.2M | ||
| Q3 24 | $237.5M | $613.3M | ||
| Q2 24 | $252.2M | $574.8M | ||
| Q1 24 | $275.2M | $573.6M |
总资产TARSTGLS
| Q4 25 | $562.2M | $1.3B | ||
| Q3 25 | $534.6M | $1.2B | ||
| Q2 25 | $495.0M | $1.2B | ||
| Q1 25 | $500.8M | $1.1B | ||
| Q4 24 | $377.0M | $1.0B | ||
| Q3 24 | $376.3M | $996.3M | ||
| Q2 24 | $376.8M | $942.5M | ||
| Q1 24 | $349.3M | $981.6M |
负债/权益比TARSTGLS
| Q4 25 | 0.21× | 0.24× | ||
| Q3 25 | 0.22× | 0.15× | ||
| Q2 25 | 0.22× | 0.15× | ||
| Q1 25 | 0.21× | 0.16× | ||
| Q4 24 | 0.32× | 0.18× | ||
| Q3 24 | 0.30× | 0.21× | ||
| Q2 24 | 0.28× | 0.25× | ||
| Q1 24 | 0.11× | 0.28× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.3M | $31.0M |
| 自由现金流经营现金流 - 资本支出 | $13.0M | $11.4M |
| 自由现金流率自由现金流/营收 | 8.6% | 4.7% |
| 资本支出强度资本支出/营收 | 4.2% | 8.0% |
| 现金转化率经营现金流/净利润 | — | 1.19× |
| 过去12个月自由现金流最近4个季度 | $-22.3M | $34.5M |
8季度趋势，按日历期对齐
经营现金流TARSTGLS
| Q4 25 | $19.3M | $31.0M | ||
| Q3 25 | $18.3M | $40.0M | ||
| Q2 25 | $-29.4M | $17.9M | ||
| Q1 25 | $-20.7M | $46.9M | ||
| Q4 24 | $-22.2M | $61.1M | ||
| Q3 24 | $-8.7M | $41.5M | ||
| Q2 24 | $-14.4M | $34.5M | ||
| Q1 24 | $-37.8M | $33.4M |
自由现金流TARSTGLS
| Q4 25 | $13.0M | $11.4M | ||
| Q3 25 | $16.3M | $21.2M | ||
| Q2 25 | $-30.4M | $-14.7M | ||
| Q1 25 | $-21.2M | $16.5M | ||
| Q4 24 | $-22.3M | $35.4M | ||
| Q3 24 | $-8.9M | $17.8M | ||
| Q2 24 | $-15.4M | $14.2M | ||
| Q1 24 | $-38.0M | $23.6M |
自由现金流率TARSTGLS
| Q4 25 | 8.6% | 4.7% | ||
| Q3 25 | 13.8% | 8.2% | ||
| Q2 25 | -29.6% | -5.7% | ||
| Q1 25 | -27.1% | 7.4% | ||
| Q4 24 | -33.5% | 14.8% | ||
| Q3 24 | -18.6% | 7.5% | ||
| Q2 24 | -37.8% | 6.5% | ||
| Q1 24 | -137.5% | 12.2% |
资本支出强度TARSTGLS
| Q4 25 | 4.2% | 8.0% | ||
| Q3 25 | 1.6% | 7.2% | ||
| Q2 25 | 1.0% | 12.7% | ||
| Q1 25 | 0.8% | 13.7% | ||
| Q4 24 | 0.1% | 10.7% | ||
| Q3 24 | 0.6% | 9.9% | ||
| Q2 24 | 2.5% | 9.2% | ||
| Q1 24 | 0.6% | 5.1% |
现金转化率TARSTGLS
| Q4 25 | — | 1.19× | ||
| Q3 25 | — | 0.85× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 1.11× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.98× | ||
| Q1 24 | — | 1.13× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
TARS
暂无分部数据
TGLS
| Product Sales | $164.2M | 67% |
| Fixed Price Contracts | $81.1M | 33% |
| Related Party | $692.0K | 0% |
